Muscular Dystrophy (MD) is a genetic condition causing progressive muscle weakness and complications in vital organs. Early ...

Matilda Baptiste is 16 from Hall Green needs help to buy vital equipment to help her live independently with Duchenne ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...

Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarterPratteln, Switzerland, January 16, 2025 – ...

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting ...

The results suggest that prolonging ambulation may not adversely impact cardiac function in adulthood for patients with ...

Santhera Pharmaceuticals’ Agamree (vamorolone) has been accepted by the Scottish Medicines Consortium (SMC) to treat Duchenne ...

Wheeling around the gym, always smiling, always chatting it up with players, Brandon Wechsler brought a charm and positivity ...

An estimated 1 in 8,000 individuals, or 870,000 people worldwide, are affected by Facioscapulohumeral muscular dystrophy ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on SLDB stock, giving a Buy rating yesterday.Stay Ahead of the ...